Tilray (NASDAQ:TLRY) is an American-owned licensed producer based in Nanaimo, BC. The company produces an array of cannabis and cannabis-related products.

It sells domestically in Canada, and to many other countries around the world. In Canada, Tilray has been supplying the medical cannabis market for several years. While Tilray was founded five years ago, it remained privately owned until 2018.

Tilray launched at US$17 during its NASDAQ IPO on July 9, 2018 and quickly shot up from there. There are a number of factors influencing Tilray’s stock price, including industry speculation and sentiment.

For example, upon rumors of a possible partnership with big alcohol player Diageo (LSE:DGE), Tilray’s stock price shot up roughly 34 percent.

Many believe that Tilray could be the top pick for this very coveted suitor. The market has also responded favorably to its quarterly earnings reports, and that has been reflected in its growing price.

Of course, market watchers are curious about how the Tilray stock price will react to two pivotal future events: legalization day in Canada on October 17, 2018, and (potential) federal legalization in the US.

Like its peers, the company’s market cap is currently considered grossly out of step with its reported earnings. After cannabis becomes legal it will become clear what the actual market demand is and whether the numbers stack up.

Some say the company’s share price and market cap will begin to recalibrate to reflect actual assets and profits after legalization occurs. But only time will tell if the penny will drop, or if prices will remain high.

Certainly anticipation for a potential federal US market could keep sentiment riding high for some time to come. With the US population being roughly 10 times that of Canada, federal legalization in the US would mean enormous growth potential, which would logically get reflected in the Tilray stock price.

With the industry just getting started, Tilray’s stock price might have even greater heights ahead.

Don’t forget to follow us @INN_Cannabis for real-time updates!

Securities Disclosure: I, Amanda Kay, hold no direct investment interest in any company mentioned in this article. 

 Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) announces that Philip Young, CEO and Director, and Maghsoud Dariani, Chief Science Officer will be presenting on Thursday, February 25th, 2021 at 5:45 pm EST at “The Gold Standard in Psychedelic Investment, Psychedelic Capital Virtual Investment Conference”, a platform showcasing the top companies, latest IPOs, newest opportunities, and deepest industry insights.

As a presenting sponsor, the Company will connect directly with some of the earliest moving investors in the psychedelic industry and reach an audience of 2,000+ investors. Presentations are 30 minutes in length, with 10 minutes allocated to a one-on-one Q&A session with the audience.

Keep reading... Show less

As Canadian operators race to strengthen their positions in the cannabis landscape, are international pursuits outside North America still top of mind?

The role that mergers and acquisitions (M&A) have played in the expansion of Canadian companies across the globe has been monumental for the growth of the cannabis industry. Now the space has reached a critical point as the demands of the US market increase.

Keep reading... Show less

It’s been just over a year since recreational cannabis was legalised in the Australian Capital Territory (ACT), home to the nation’s capital city of Canberra.

Announced on September 25, 2019, and brought into effect on January 31, 2020, the rules make it legal to possess and personally use small amounts of cannabis.

Keep reading... Show less

Pac Roots Cannabis Corp. (CSE: PACR) (“PacRoots” or the “Company”), announces the closing of its previously announced non-brokered private placement (see press release dated January 25, 2021).

Aggregate gross proceeds of $1,340,685.90 were raised through the issuance of 7,448,255 units (each a “Unit”). Each Unit consists of one common shares and one share purchase warrant. Each warrant is exercisable at a price of $0.30 per share until February 23, 2024.

Keep reading... Show less

 Trulieve Cannabis Corp. (“Trulieve” or the “Company”) (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States will release its fourth quarter 2020 financial results on Tuesday, March 23, 2021 before markets open. Following the earnings release, management will host a conference call at 8:30 AM Eastern Time to review the financial results.

All interested parties can join the conference call by dialing 1-888-231-8191 or 1-647-427-7450, conference ID: 7066881. Please dial in 15 minutes prior to the call to secure a line. The conference call will be archived for replay until March 30, 2021 . To access the archived conference call, please dial 1-855-859-2056 and enter the encore code 7066881.

Keep reading... Show less